OS Therapies (NYSEAMERICAN:OSTX) Lowered to "Strong Sell" Rating by Zacks Research

Key Points

• OS Therapies has been downgraded from a "hold" rating to a "strong sell" rating by Zacks Research.
• Despite this downgrade, D. Boral Capital has maintained a "buy" rating with a price target of $20.00 for the stock.
• The stock is currently trading at approximately $1.95, which is significantly below its 1 year high of $7.00, indicating a volatile performance.

OS Therapies (NYSEAMERICAN:OSTX - Get Free Report) was downgraded by research analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a research note issued on Monday,Zacks.com reports.

Separately, D. Boral Capital reissued a "buy" rating and set a $20.00 price target on shares of OS Therapies in a report on Friday, October 10th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $18.00.

OS Therapies Stock Performance

Shares of OSTX stock opened at $1.95 on Monday. The stock's 50-day moving average is $2.12 and its two-hundred day moving average is $1.84. The firm has a market cap of $61.72 million, a price-to-earnings ratio of -2.47 and a beta of -4.09. OS Therapies has a 1 year low of $1.12 and a 1 year high of $7.00.

Institutional Investors Weigh In On OS Therapies

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bridgeway Capital Management LLC purchased a new stake in OS Therapies in the 2nd quarter valued at approximately $47,000. XTX Topco Ltd acquired a new position in OS Therapies in the 2nd quarter valued at $63,000. Finally, CM Management LLC raised its holdings in OS Therapies by 172.6% in the 1st quarter. CM Management LLC now owns 300,000 shares of the company's stock valued at $462,000 after acquiring an additional 189,956 shares during the last quarter.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.